Hearing Loss. Ototoxic hearing loss
Conditions
Interventions
Intervention 1: Intervention group: At first, Case-ear is filled with Xyla-P ointment. After 5 minute local anesthesia , ointment was suctioned under microscope. 0.7-1 cc of Diltiazem solution (5mg/ml
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years old Presence of Acoustic Reflex or Tympanometry A In PTA, average hearing threshold at frequencies of 3000-5000 or 8000 to 4000 less than 40 dB In PTA, the hearing threshold on either side should not be asymetric within 3000 to 5000 or 8000-4000 Hz frequencies or there is less than 10 dB The karnofsky index is equal to or greater than 70
Exclusion criteria
Exclusion criteria: History of previous internal ear disease that may reduce the sensory nervous system hearing History of Meniere's disease Or fluticating hearing loss Observing pathologic findings in otoscopy Previously cisplatin has not been treated Radiation History to the head and neck Area Candidate for radiation to the head and neck Liver and Renal failure Conductive hearing loss more than 5 dB Heart problems, such as hypotension or AV block
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Ototoxicity Grade. Timepoint: One week and one month after the last dose of cisplatin. Method of measurement: Audiometry( Grade changes).;Complications of cisplatin injection. Timepoint: One week and one month after the last dose of cisplatin. Method of measurement: Questions From Patient. | — |
Primary
| Measure | Time frame |
|---|---|
| Hearing Loss. Timepoint: One week and one month after the last dose of cisplatin. Method of measurement: Audiometry Test.;Low-frequency Average hearing threshold. Timepoint: One week and one month after the last dose of cisplatin. Method of measurement: Audiometry Test.;High-frequency Average hearing threshold. Timepoint: One week and one month after the last dose of cisplatin. Method of measurement: Audiometry Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mirmohammad Jalali
Iran University of Medical Sciences
Outcome results
None listed